Skip to main content

Table 1 Patient Demographic Data A total of 54 metastatic breast cancer patients were recruited for this study

From: CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome

  

(n = 54)

Age (median)

 

57 years

Gender

Female

54 (100%)

Race

Asian

4 (7%)

 

Black

4 (7%)

 

Hispanic

1 (2%)

 

White

33 (61%)

 

Other/unknown

12 (22%)

Grade

0

1 (2%)

 

1

1 (2%)

 

2

14 (26%)

 

3

21 (39%)

 

Unknown

17 (31%)

Histology

IDC*

48 (76%)

 

ILC

3 (5%)

 

Unknown

12 (19%)

Estrogen receptor

Positive( +)

22 (41%)

 

Negative (−)

27 (50%)

 

Unknown

5 (9%)

Progesterone receptor

Positive ( +)

13 (24%)

 

Negative (-)

37 (69%)

 

Unknown

4 (7%)

HER2 receptor

Positive ( +)

11 (20%)

 

Negative (−)

40 (74%)

 

Unknown

3 (6%)

TNBC

 

20 (37%)

CAMLs present

 

53 (98%)

Average CAMLs per patient

5 CAMLs

 

CTCs present

 

34 (63%)

Average CTCs per patient

 

4 CTCs

Average prior therapies

 

3

  1. Number of average prior therapies was calculated using patients with a confirmed number of prior therapies. *9 IDC patients were of the IBC subtype
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us